Manila Times Business
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company’s common stock, with a per
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Guggenheim Investments Announces June 2026 Closed-End Fund Distributions
1h ago
University of Miami Miller School of Medicine Names Dr. Pradeep Ramulu Chair of Ophthalmology and the Bascom Palmer Eye Institute
1h ago
Xometry Announces Proposed Public Offering of Class A Common Stock
1h ago
Hallador Energy Acquires 460 MW of Siemens Turbines for $350 Million, Accelerating Merom Natural Gas Generation Project
1h ago